866-997-4948(US-Canada Toll Free)

C5a Anaphylatoxin Chemotactic Receptor 1-Pipeline Review, H2 2019

Published By :

Global Markets Direct

Published Date : Nov 2019

Category :

Pharmaceutical

No. of Pages : 64 Pages

C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2019

Summary

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production.

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Filing rejected/Withdrawn, Phase II and Preclinical stages are 1, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders and Respiratory which include indications Autoimmune Disorders, Allergic Asthma, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hepatocellular Carcinoma, Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Motor Neuron Diseases, Neuroinflammation, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Pain, Periodontitis, Renal Cell Carcinoma, Rheumatoid Arthritis and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2019, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
Alsonex Pty Ltd
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
Nov 05, 2019: Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)
Oct 01, 2019: Innate Pharma presents early clinical data on IPH5401 at the ESMO 2019 congress
Sep 23, 2019: Innate Pharma announces clinical data presentation on IPH5401 at ESMO 2019
Jan 24, 2019: ChemoCentryx announces withdrawal of phase II-based conditional marketing authorisation (CMA) application for ANCA-associated vasculitis in Europe, phase III advocate trial data release planned for Q4 2019
Oct 25, 2018: ChemoCentryx announces presentation of data on Avacopan, a complement 5a receptor inhibitor, at ASN Kidney Week 2018
Sep 12, 2018: Innate pharma announces enrollment of first patient in the Phase I study of IPH5401 in combination with durvalumab (Imfinzi) in solid tumors
May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress
Apr 11, 2018: ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Jan 04, 2018: Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017
Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan
May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alsonex Pty Ltd, H2 2019
Pipeline by ChemoCentryx Inc, H2 2019
Pipeline by Dompe Farmaceutici SpA, H2 2019
Pipeline by Innate Pharma SA, H2 2019
Pipeline by MorphoSys AG, H2 2019
Pipeline by Prommune Inc, H2 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *